Metformin/Glimepiride and Metformin/Glibenclamide, Which is Better?: A Systematic Review and Meta-Analysis
Abstract
Background: Type 2 diabetes mellitus (DM) is associated with the microvascular and macrovascular complication. Metformin and sulphonylurea (glimepiride and glibenclamide) combination is widely used for the treatment of type 2 DM. This study aimed to examine the difference of Metformin/Glimepiride and Metformin/Glibenclamide administrations in reducing HbA1C among type 2 DM patients.
Subjects and Method: This was a systematic review and meta-analysis according to PRISMA guideline with PICO construction using MeSH and text-word. 214 article were identified from PubMed, Cochrane, other source databases. Two articles with 183 type 2 DM patients were selected for this study.
Results: No significant difference on HbA1C level, fasting plasma glucose, and hypoglycemia adverse events between glimepiride/metformin and glibenclamide/metformin combinations. However, glimepiride/metformin combination demonstrated lower HbA1C (-0.11; 95% CI= -0.41 to 0.18; p= 0.450) and lower hypoglycemia adverse events (OR= 0.52; 95% CI= -1.02 to 3.05; p= 0.450), while glibenclamide/metformin combination demonstrated lower fasting plasma glucose concentration (1.01; 95% CI= -1.02 to 3.05; p= 0.450).
Conclusion: Glimepiride/metformin combination is preferable in HbA1C lowering and hypoglycemia risk than glibenclamide/metformin combination.
Keywords: Glimepiride-metformin, Glibenclamide-metformin, type 2 diabetes mellitus
Correspondence: Yedy Purwandi Sukmawan. Department of Clinical Pharmacy and Pharmacology, Institute of Health Science of Bakti Tunas Husada Tasikmalaya, West Java, Indonesia. Email: yedipur@gmail.com
Indonesian Journal of Medicine (2019), 4(3): 211-218
https://doi.org/10.26911/theijmed.2019.04.03.03
References
Aamir SKAH, Raza A, Das AK, Khan AKA, Shrestha D, Qureshi F, et al. (2015). Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 19(5): 577–96. https://dx.doi.org/10.4103%2F2230-8210.163171
American Diabetes Association (2018). Standards of medical care in diabetes—2018 abridged for primary care providers. Clinical Diabetes; 36 (1): 14-37. Doi: 10.2337/cd17-0119.
Arnold LW, Wang Z (2014). The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud. 11(2): 138-52. doi: 10.1900/RDS.2014.11.138.
Chawla A, Chawla R, Jaggi S (2016). Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?. Indian J Endocrinol Metab. 20(4): 546–51. https://dx.doi.org/10.4103%2F2230-8210.183480.
Forouhi NG, Wareham NJ (2014). Epidemiology of diabetes. Medicine (Abingdon). 42(12): 698–702. https://dx.doi.-org/10.1016%2Fj.mpmed.2014.09.007.
González-Ortiza M, Guerrero-Romeroc JF, Violante-Ortizd R, Wacher-Rodartee N, -Abundisa EM, Aguilar-Salinasf C, et al. (2009). Efficacy of glimepiride/ metformin combination versus glibenclamide/ metformin in patients with uncontrolled type 2 diabetes mellitus. Journal of Diabetes and Its Complications; 23:376–379. doi: 10.1016/j.jdiacomp.2008.09.002.
Hu S, Wang S, Fanelli B, Bell PA, Dunning BE, Geisse S et al (2000). Pancreatic beta-cell K (ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther. 293(2):444-52.
Juarez DT, Ma C, Kumasaka A, Shimada R, Davis J (2014). Failure to reach target glycated a1c levels among patients with diabetes who are adherent to their antidiabetic medication. Popul Health Manag; 17(4): 218–23.
Kramer W, Müller G, Geisen K (1996). Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at beta-cells. Horm Metab Res. 28(9):464-8.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6(7):e1000097. doi: 10.1371/journal.pmed.1000097.
Muller G (2005). The mode of action of the antidiabetic drug glimepiride-beyond insulin secretion. current medicinal chemistry. Immunology, Endocrine Metabolic Agents. 5(6): 499-518. doi: 10.2174/156801305774962123.
Rani M, Yadav S, Gupta P, Pandey S, Choudhary S (2014). A study comparing the effect of glimepiride and glibenclamide on glycosylated haemoglobin (Hba1c) in type II diabetes mellitus patients. IJMSPH. 3(1): 35-7. https://-dx.doi.org/10.5455/ijmsph.2013.200920134.
Ridle MC, Bakris G, Blonde L, Boulton AJM, D’Alesio D, De Groot M, et al. (2018). Professional practice committee: Standards of medical care in diabetes – 2018. Diabetes Care. 41(1): S3. https://doi.org/10.2337/dc18-Sppc01
Shimpi RD, Patil PH, Kuchake VG, Ingle PV, Surana SJ, Dighore PN (2009). Comparison of effect of metformin in combination with glimepiride and glibenclamide on glycaemic control in patient with type 2 diabetes mellitus. Int.J. PharmTech Res; 1(1):50-61.
Van Dalem J, Brouwers MCGJ, Stehouwer CDA, Leufkens HGM, Driessen JHM, De Fries, Burden AM (2016). Risk of hypoglycemia in users of sulphonylureas compared with metforminin relation to renal function and metabolite group: population based cohort study. BMJ, 354: i3625. https://doi.org/10.1136/bmj.i3625
